cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Allogene Therapeutics Inc
10 own
13 watching
Current Price
$0
$-0.2
(-2.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,111.92M
52-Week High
52-Week High
17.49
52-Week Low
52-Week Low
5.405
Average Volume
Average Volume
0.31M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,111.92M
icon52-Week High17.49
icon52-Week Low5.405
iconAverage Volume0.31M
iconDividend Yield--
iconP/E Ratio--
What does the Allogene Therapeutics Inc do?
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company has a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to deliver intracellular RNA or DNA into lymphocytes, including T cells. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More
How much money does Allogene Therapeutics Inc make?
News & Events about Allogene Therapeutics Inc.
Globe Newswire
14days ago
Preclinical Efficacy and Safety Results Indicate AlloCAR TDevelopment Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering ...
Globe Newswire
15days ago
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple MyelomaSOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.(Nasdaq: ALLO), a clinical-stage biotechnology company ...
Globe Newswire
16days ago
NEW YORK, Jan. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders. The investigation concerns potential ...
PR Newswire
1month ago
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm...
Globe Newswire
1month ago
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive ...
Frequently Asked Questions
Frequently Asked Questions
What is Allogene Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Allogene Therapeutics Inc shares?
plus_minus_icon
How can I buy Allogene Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Allogene Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Allogene Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Allogene Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Allogene Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Allogene Therapeutics Inc?
plus_minus_icon
What percentage is Allogene Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Allogene Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.2
(-2.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00